About Penta
Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta Foundation UK
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Diversity & Inclusion
Brighter Future Award
Archivio
🇬🇧 Easy-to-take medicine better at suppressing HIV in children
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Once-daily DTG more effective in treating HIV in children
Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1
Ethical youth engagement in the HIV response
Dolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV
Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study
REACH project published in CORDIS
Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART
Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial
World AIDS Day 2021: How paediatric HIV has changed in the last 30 years